- Tiziana Life Sciences (NASDAQ:TLSA) has initiated a collaborative clinical study investigating nasally administered Foralumab either alone or in combination with orally administered dexamethasone in COVID-19 patients in Brazil.
- Harvard Medical School, Santa Casa de Misericórdia de Santos Hospital (Jabaquara, Santos, Brazil) and Tiziana are closely collaborating to facilitate initiation of this study in expedited time frames.
- Patients dosing will start on November 3, with clinical data expected to be available before year-end.
- https://seekingalpha.com/news/3629434-tiziana-launches-foralumab-study-for-covidminus-19-in-brazil-clinical-data-expected-year-end
Monday, November 2, 2020
Tiziana launches foralumab study for COVID-19 in Brazil; eyes data by year end
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.